gabexate has been researched along with n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adriaenssens, Y; Augustyns, K; De Winter, H; Gladysz, R; Joossens, J; Lambeir, AM; Van der Veken, P | 1 |
| Pilgram, O; Steinmetzer, T; Wenzel, BM; Wiedemeyer, SJA | 1 |
2 other study(ies) available for gabexate and n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride
| Article | Year |
|---|---|
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Topics: Catalytic Domain; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Molecular Docking Simulation; Pyridines; Structure-Activity Relationship; Urokinase-Type Plasminogen Activator | 2015 |
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
Topics: Animals; Antifibrinolytic Agents; Catalytic Domain; Crystallography, X-Ray; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans; Ligands; Molecular Structure; Plasminogen; Protein Binding; Protein Domains | 2020 |